Activation of Akt involves resistance to NF-κB inhibition and abrogation of both triggers synergistic apoptosis in lung adenocarcinoma cells.

Lung Cancer

Department of Hematology, School of Medicine, Kitasato University, 1-15-1 Minami-ku, Kitasato, Sagamihara, Kanagawa 252-0374, Japan. Electronic address:

Published: February 2014

AI Article Synopsis

  • The study aims to analyze the connection between the NF-κB and PI3K-Akt-mTOR pathways in lung cancer cell survival, as their interaction is not well understood.
  • Researchers investigated these pathways in lung adenocarcinoma cells, testing the effects of various inhibitors.
  • Findings revealed that while NF-κB was continuously active in most cases, resistance to its inhibition was linked to the Akt-mTORC1-S6K pathway, suggesting that targeting Akt could enhance the effectiveness of NF-κB inhibition and induce cell death more effectively.

Article Abstract

Objectives: Although nuclear factor (NF)-κB and phosphoinositide 3-kinase (PI3K)-Akt-mTOR comprise key pathways, their interrelationship in lung cancer cell survival is poorly understood and needs further analyses.

Materials And Methods: We examined the activation of the NF-κB and Akt-mTORC1-p70 S6 kinase (S6K) pathways and the effect of inhibitors for NF-κB, mTORC1, and Akt using fresh lung adenocarcinoma cells.

Results: The cases used for this study showed constitutive NF-κB activity; however, all cases but one showed resistance to NF-κB inhibition. Further examination revealed that the resistant cases were also active in the Akt-mTORC1-S6K pathway. These cases were insensitive to mTORC1 inhibition but sensitive to Akt inhibition. Akt inhibition recovered sensitivity to NF-κB inhibition and dual inhibition showed a synergistic effect on apoptosis induction.

Conclusion: These results indicate that the activation of Akt involves resistance to NF-κB inhibition and both pathways synergistically support the survival of lung adenocarcinoma cells. The results also indicate that inhibition of the mTORC1-S6K pathway does not inhibit the survival of these cells.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2013.10.018DOI Listing

Publication Analysis

Top Keywords

nf-κb inhibition
16
resistance nf-κb
12
lung adenocarcinoma
12
inhibition
9
activation akt
8
akt involves
8
involves resistance
8
nf-κb
8
synergistic apoptosis
8
adenocarcinoma cells
8

Similar Publications

Cystine-Modified Lignin-Copper Coordination Nanocarriers Improve the Therapeutic Efficacy of Tyrosine Kinase Inhibition via Cuproptosis.

ACS Appl Mater Interfaces

January 2025

Department of Radiology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, No. 651 Dongfeng Road East, Guangzhou, Guangdong 510060, P. R. China.

The clinical application of tyrosine kinase inhibitors (TKIs) is rapidly growing and has emerged as a cornerstone in the treatment of both solid tumors and hematologic malignancies. However, resistance to TKI targets and disease progression remain inevitable. Nanocarrier-mediated delivery has emerged as a promising strategy to overcome the limitations of the TKI application.

View Article and Find Full Text PDF

Background: The global aging population and rapid development of digital technology have made health management among older adults an urgent public health issue. The complexity of online health information often leads to psychological challenges, such as cyberchondria, exacerbating health information avoidance behaviors. These behaviors hinder effective health management; yet, little research examines their mechanisms or intervention strategies.

View Article and Find Full Text PDF

Bacterial infections pose a serious threat to human health. For many years, there has been a search for materials that would inhibit their development. It was decided to take a closer look at various elastomeric materials with the addition of chitosan.

View Article and Find Full Text PDF

Deciphering the complex clonal heterogeneity of polycythemia vera and the response to interferon alpha.

Blood Adv

January 2025

Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, Medical Faculty, RWTH Aachen University, Aachen, Germany.

Interferon alpha (IFNa) is approved for the therapy of patients (pts) with polycythemia vera (PV), a subtype of myeloproliferative neoplasms (MPN). Some pts achieve molecular responses (MR), but clonal factors sensitizing for MR remain elusive. We integrated colony formation and differentiation assays with single-cell RNA seq and genotyping in PV-derived cells vs.

View Article and Find Full Text PDF

The global prevalence of heart failure is still growing, which imposes a heavy economic burden. The role of microRNA-146b (miR-146b) in HF remain largely unknown. This study aims to explore the role and mechanism of miR-146b in HF.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!